Traditional treatments like inhaled steroids and bronchodilators help manage symptoms but fail to address the underlying cause: the immune system’s misdirected attack on respiratory allergens.

But what if we could reprogram the immune system to tolerate these allergens rather than react with inflammation?

A team of researchers led by Jeffrey Hubbell, Vice President of Life Sciences and Engineering at New York University and Professor of Chemical and Biomolecular Engineering at NYU Tandon, of Biology and Chemistry at NYU Faculty of Arts and Science, and Biochemistry and Molecular Pharmacology at NYU Langone Health along with researchers at the UChicago Pritzker School of Molecular Engineering have developed a new therapy that does just that—by enlisting an unexpected ally: the liver.